Search Within

Department of Medicine

Formats
  1. Journal Article (19627)
  2. Meeting Abstract (16084)
  3. Review (1160)
  4. Book Section (934)
  5. Editorial (612)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22376)
  2. Hematologic Malignancies, Division of (13310)
  3. Center for Hematologic Malignancies (11084)
  4. GSK Faculty (10660)
  5. Survivorship Research (9357)
  6. Division of Subspecialty Medicine (7562)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1168)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4217)
  3. American Society of Hematology (4004)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2306)
  6. Nature Publishing Group (2123)

More Publishers

Results (39721)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunotherapy and transarterial radioembolization combination treatment for advanced hepatocellular carcinoma
    Journal Article

    Yeo, Y. H.; Liang, J.; Lauzon, M.; Luu, M.; Noureddin, M.; Ayoub, W.; Kuo, A.; Sankar, K.; Gong, J.; Hendifar, A.; more...
    American Journal of Gastroenterology (2023)

    Fulltext@MSK | Save
  • KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRAS(G12C) mutation
    Meeting Abstract

    Pant, S.; Yaeger, R.; Spira, A. I.; Pelster, M.; Sabari, J. K.; Hafez, N.; Barve, M. A.; Velastegui, K.; Yan, X. H.; Der-Torossian, H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer
    Meeting Abstract

    Janjigian, Y. Y.; Oh, D. Y.; Pelster, M.; Wainberg, Z. A.; Sison, E. A. R.; Scott, J. R.; Ronayne, J.; Wishengrad, D.; Rhee, J.; Nuyten, D. S. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Inhibition of ceramide rich platforms by anti-ceramide immunotherapy prevents retinal endothelial cell damage and the development of diabetic retinopathy
    Meeting Abstract

    Dorweiler, T. F.; Singh, A.; Kolesnick, R. N.; Busik, J. V.
    Investigative Ophthalmology & Visual Science (IOVS) (2023)

    Fulltext@MSK | Save
  • Modern associations of uterine carcinomas with prior exposure to tamoxifen
    Meeting Abstract

    Rios-Doria, E.; Hodgson, A.; Aviki, E.; Zivanovic, O.; Friedman, C.; Aghajanian, C.; Makker, V.; Liu, Y.; Zamarin, D.; Leitao, M.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Germline drivers of gynecologic carcinosarcoma
    Meeting Abstract

    Sia, T.; Birsoy, O.; Kemel, Y.; Maio, A.; Salo-Mullen, E.; Sheehan, M.; Hensley, M.; Rubinstein, M.; Makker, V.; Grisham, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes
    Meeting Abstract

    Praiss, A.; Park, K.; Zhou, Q.; White, C.; Iasonos, A.; Zivanovic, O.; Abu-Rustum, N.; Weigelt, B.; Aghajanian, C.; Grisham, R.
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma
    Meeting Abstract

    Makker, V.; Vergote, I.; Mirza, M.; Coleman, R.; Fidalgo, J. A. P.; Monk, B.; Valabrega, G.; Slomovitz, B.; van Gorp, T.; Moore, K.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Response to treatment with nab-sirolimus among patients with primary uterine PEComa: A sub analysis from AMPECT
    Meeting Abstract

    Palma, N.; Navarro, W.; Ravi, V.; Dickson, M.; Ganjoo, K.; Ding, L.; Schmid, A.; Wagner, A.
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
    Meeting Abstract

    Lee, E.; Rodon, J.; Demeure, M.; Deming, D.; Federman, N.; McKean, M.; Spira, A.; Kwiatkowski, D.; Hussein, M.; Gordon, E.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save